Suppr超能文献

通过对丹特氏病(CLCN5基因突变)及其他肾小管疾病的研究定义的肾小管性蛋白尿。

Tubular proteinuria defined by a study of Dent's (CLCN5 mutation) and other tubular diseases.

作者信息

Norden A G, Scheinman S J, Deschodt-Lanckman M M, Lapsley M, Nortier J L, Thakker R V, Unwin R J, Wrong O

机构信息

Department of Chemical Pathology, Chase Farm Hospitals NHS Trust, Enfield, Middlesex, England.

出版信息

Kidney Int. 2000 Jan;57(1):240-9. doi: 10.1046/j.1523-1755.2000.00847.x.

Abstract

UNLABELLED

Tubular proteinuria defined by a study of Dent's ( CLCN5 mutation) and other tubular diseases.

BACKGROUND

The term "tubular proteinuria" is often used interchangeably with "low molecular weight proteinuria" (LMWP), although the former implies a definite etiology. A specific quantitative definition of tubular proteinuria is needed, and we address this by studying five different renal disorders.

METHODS

Tubular proteinuria was assessed by measuring urinary retinol-binding protein (RBP), beta2-microglobulin (beta2M), alpha1-microglobulin (alpha1M), and albumin in 138 patients: 26 affected males and 24 female carriers of the X-linked syndrome "Dent's disease," 6 patients with other Fanconi syndromes, 17 with distal renal tubular acidosis (dRTA), 39 with glomerulonephritis (GN), and 26 with Chinese herbs nephropathy (CHN).

RESULTS

RBP was better than beta2M or alpha1M in identifying the tubular proteinuria of Dent's disease. Median urinary RBP levels in mg/mmol creatinine were: affected male Dent's, 18.2, N = 26; carrier female Dent's, 0. 30, N = 24; dRTA, 0.027, N = 17; GN, 0.077, N = 39; and normal adults, 0.0079, N = 61. Elevated urinary RBP (>0.017) and albumin < (10 x RBP) + 2 identified all patients with the LMWP of Dent's disease and clearly distinguished their LMWP from that of dRTA and GN. This is a quantitative definition of tubular proteinuria. Consistent with this definition, 80% of those patients with CHN who had an elevated RBP had tubular proteinuria. Urinary RBP and albumin in carriers of Dent's disease were strikingly correlated over a 100-fold range (R = 0.933).

CONCLUSION

The combination of elevated urinary RBP (>0.017) and albumin < (10 x RBP) + 2 (mg protein/mmol creatinine) is a quantitative definition of tubular proteinuria. Furthermore, our findings suggest that a shared defect in tubular RBP and albumin reuptake causes this form of proteinuria.

摘要

未标注

通过对丹特氏病(CLCN5 突变)及其他肾小管疾病的研究定义肾小管性蛋白尿。

背景

术语“肾小管性蛋白尿”常与“低分子量蛋白尿”(LMWP)互换使用,尽管前者意味着明确的病因。需要对肾小管性蛋白尿进行具体的定量定义,我们通过研究五种不同的肾脏疾病来解决这一问题。

方法

通过测量 138 例患者尿中的视黄醇结合蛋白(RBP)、β2 -微球蛋白(β2M)、α1 -微球蛋白(α1M)和白蛋白来评估肾小管性蛋白尿:26 例患有 X 连锁综合征“丹特氏病”的男性患者和 24 例女性携带者,6 例患有其他范科尼综合征的患者,17 例患有远端肾小管酸中毒(dRTA)的患者,39 例患有肾小球肾炎(GN)的患者,以及 26 例患有中草药肾病(CHN)的患者。

结果

在识别丹特氏病的肾小管性蛋白尿方面,RBP 比β2M 或α1M 表现更好。以毫克/毫摩尔肌酐为单位的尿 RBP 水平中位数为:患有丹特氏病的男性患者,18.2,N = 26;丹特氏病的女性携带者,0.30,N = 24;dRTA,0.027,N = 17;GN,0.077,N = 39;正常成年人,0.0079,N = 61。尿 RBP 升高(>0.017)且白蛋白<(10×RBP)+ 2 可识别所有患有丹特氏病低分子量蛋白尿的患者,并能将其低分子量蛋白尿与 dRTA 和 GN 的低分子量蛋白尿清楚地区分开来。这是肾小管性蛋白尿的定量定义。与此定义一致,CHN 患者中 RBP 升高的患者中有 80%患有肾小管性蛋白尿。丹特氏病携带者的尿 RBP 和白蛋白在超过 100 倍范围内显著相关(R = 0.933)。

结论

尿 RBP 升高(>0.017)且白蛋白<(10×RBP)+ 2(毫克蛋白/毫摩尔肌酐)的组合是肾小管性蛋白尿的定量定义。此外,我们的研究结果表明肾小管 RBP 和白蛋白重吸收的共同缺陷导致了这种形式的蛋白尿。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验